Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.

Lynch M, Manoy S, Sly PD, Wainwright CE, Wolvetang E, Feenstra JE, Dowling J, Ware RS, Patel MS, Hermith-Ramirez D, Vogel A, Preece K, Zappala T, Dai S, Webber A, Yeo A, Subramanian G, Rao G, Ma CS, Jose S, Gatei M, Xin B, Sandona N, Lewindon P, Sinclair KG, Nayler S, Lavin MF, Coman DJ

Open source

DOI: 10.1016/j.ebiom.2025.105840
Published: 2025 Aug
Container: EBioMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2025.105840,
  title = {Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.},
  author = {Lynch M and Manoy S and Sly PD and Wainwright CE and Wolvetang E and Feenstra JE and Dowling J and Ware RS and Patel MS and Hermith-Ramirez D and Vogel A and Preece K and Zappala T and Dai S and Webber A and Yeo A and Subramanian G and Rao G and Ma CS and Jose S and Gatei M and Xin B and Sandona N and Lewindon P and Sinclair KG and Nayler S and Lavin MF and Coman DJ},
  year = {2025},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2025.105840},
  url = {https://doi.org/10.1016/j.ebiom.2025.105840}
}

RIS

TY  - JOUR
TI  - Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.
AU  - Lynch M
AU  - Manoy S
AU  - Sly PD
AU  - Wainwright CE
AU  - Wolvetang E
AU  - Feenstra JE
AU  - Dowling J
AU  - Ware RS
AU  - Patel MS
AU  - Hermith-Ramirez D
AU  - Vogel A
AU  - Preece K
AU  - Zappala T
AU  - Dai S
AU  - Webber A
AU  - Yeo A
AU  - Subramanian G
AU  - Rao G
AU  - Ma CS
AU  - Jose S
AU  - Gatei M
AU  - Xin B
AU  - Sandona N
AU  - Lewindon P
AU  - Sinclair KG
AU  - Nayler S
AU  - Lavin MF
AU  - Coman DJ
PY  - 2025
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2025.105840
UR  - https://doi.org/10.1016/j.ebiom.2025.105840
ER  -

APA

M, L., S, M., PD, S., CE, W., E, W., JE, F., J, D., RS, W., MS, P., D, H., A, V., K, P., T, Z., S, D., A, W., A, Y., G, S., G, R., CS, M., S, J., M, G., B, X., N, S., P, L., KG, S., S, N., MF, L., & DJ, C. (2025). Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2025.105840

Source records

pubmed · retrieved 2026-09-25T08:20:10.134Z